3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Cancer -

Beer and spirits boost colon tumor risk

CancerSep 21, 05

Beer and spirits drinkers face a higher risk of colorectal tumors, but wine drinkers may have a lower risk, according to a report in the American Journal of Gastroenterology.

“Alcohol is pernicious with regard to colorectal” tumors, Dr. Joseph C. Anderson from Stony Brook University, New York told Reuters Health. “Lifestyle plays a role as genetics does in the development” of these tumors.

Dr. Anderson and associates investigated the impact of regular alcohol consumption on colorectal tumors in 2,291 patients undergoing screening colonoscopy.

Patients defined as heavy beer or spirits drinkers had more than twice the risk of developing significant colorectal tumors, compared with abstainers or moderate consumers, the authors report. Moderate wine drinkers, on the other hand, faced about half the risk experienced by abstainers.

Colorectal tumors were also associated with age older than 60 years, smoking and obesity, the report indicates.

The investigators note that “patients who regularly drink spirits have an increased risk for significant colorectal (tumors) and perhaps should be targeted for risk modification by their gastroenterologist in addition to their primary care physician.”

In fact, Anderson noted, “I would target anyone who has more than one beer or drink per day.” He added that he and his colleagues are currently comparing the effects of red and white wine.

Red wine, “due to high levels of (the natural antioxidant) resveratrol,” he added, should be even more protective against colorectal tumors than white wine.

SOURCE: American Journal of Gastroenterology, September 2005.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors
  UW research shows sensor technology may help improve accuracy of clinical breast exams

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site